Monoclonal antibody · Antagonist of CD73 (5'-ecto-nucleotidase) (NT5E) · developed by Corvus Pharmaceuticals
Mupadolimab is a humanized IgG1 monoclonal antibody that binds the ectoenzyme CD73 (NT5E) on tumor cells, leading to its internalization and blocking conversion of AMP to adenosine. It is being studied in multiple solid tumors and lymphoma, alone and in combination with other agents.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04734873 | Phase 3 | Covid-19 | Terminated | CRVS |
| NCT03454451 | Phase 1 | Non-Small Cell Lung Cancer | Completed | CRVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder CancerCervical CancerColorectal CancerCovid-19Endometrial CancerMetastatic Castration Resistant Prostate CancerNon-hodgkin LymphomaNon-Small Cell Lung CancerOvarian CancerPancreatic CancerRenal Cell CancerSarcomaSquamous Cell Carcinoma of the Head and NeckTriple Negative Breast Cancer
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRVS page.
See CRVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRVS catalysts and pipeline →